Skip to main content

Table 4 Haematological & Non-haematological toxicity per treatment arm

From: A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

 

DC

(n = 67)

D

(n = 65)

DC

(n = 67)

D

(n = 65)

P-value

 

GrIII

GrIII

GrIV

GrIV

 
 

N

%

N

%

N

%

N

%

 

Neutropenia

7

10.4

3

4.6

4

6.0

1

1.5

0.098

Anaemia

3

4.5

-

-

-

-

-

-

0.791

Thrombocytopenia

2

3.0

-

-

-

-

-

-

< 0.001

Febrile neutropenia

-

-

-

-

-

-

-

-

 

Nausea

-

-

-

-

-

-

-

-

0.128

Vomiting

-

-

-

-

-

-

-

-

0.999

Diarrhoea

2

3.0

1

1.5

1

1.5

-

-

0.999

Stomatitis

-

-

-

-

-

-

-

-

0.027

Constipation

-

-

-

-

-

-

-

-

0.274

Neuromuscular

-

-

-

-

-

-

-

-

0.999

Neurosensory

-

-

-

-

-

-

-

-

0.678

Allergy

2

3.0

-

-

-

-

1

1.6

0.680

Fatigue

-

-

6

9.2

-

-

1

1.5

0.015

Oedema

-

-

-

-

-

-

-

-

0.680

Other

        

0.999

  1. P-value for Neutropenia: for grade III/IV vs 0-II between the two groups
  2. P-value for Anaemia: for grade II-IV vs 0/I between the two groups
  3. P-value for Thrombocytopenia: for any grade vs grade O between the two groups
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us